Senotoxins target senescence via lipid binding specificity, ion imbalance and lipidome remodeling
Javier Moral-Sanz1,2, Isabel Fernández-Carrasco3, Valentina Ramponi4
1Translational Venomics Group, Madrid Institute for Advanced Studies in Nutrition (IMDEA Nutrition), Madrid, Spain. javier.moralsanz@syneoshealth.com.
Abstract:
Senescence is a driver of aging and a barrier to tumor progression, but its persistent accumulation drives inflammation and relapse. Thus, the success of chemotherapy could be jeopardized when senescence emerges in the tumor microenvironment. Here we identified the senolytic properties of a pore-forming toxin, sticholysin I (StnI). StnI and our engineered improved form, StnIG, selectively hampers viability of chemotherapy-induced senescent cancer cells, as well as senescent primary cells. We show that its selectivity is mediated by specific binding and lipid ratios associated with senescence, including compromised membrane bilayer asymmetry. Mechanistically, StnIG triggers sodium and calcium influx and an enduring potassium efflux in senescent cells. Calcium triggers the opening of calcium-activated potassium channels, leading to cell death by apoptosis and pyroptosis. Finally we show that StnIG synergizes with senescence-inducing chemotherapy to drive remission of solid tumors in mice. Our findings define StnI and StnIG as senotoxins with translational potential for cancer therapy.
Insights
Sticholysin I (StnI) and its variant StnIG are novel senotoxins that selectively kill senescent cancer cells. This discovery offers a new strategy to enhance chemotherapy effectiveness and treat solid tumors.
Area of Science:
- Cellular senescence
- Cancer biology
- Pharmacology
Background:
- Cellular senescence drives aging and hinders tumor progression but can promote inflammation and relapse.
- Persistent senescent cells in the tumor microenvironment can compromise chemotherapy efficacy.
Purpose of the Study:
- To identify and characterize senolytic agents targeting chemotherapy-induced senescent cells.
- To explore the therapeutic potential of sticholysin I (StnI) and its engineered variant (StnIG) in cancer therapy.
Main Methods:
- Investigated the senolytic properties of StnI and StnIG on senescent cancer and primary cells.
- Analyzed the mechanism of action, including membrane binding and ion flux.
- Evaluated the in vivo efficacy of StnIG in combination with chemotherapy in mouse models of solid tumors.
Main Results:
- StnI and StnIG selectively reduced the viability of senescent cells.
- Selectivity is mediated by binding to specific lipids and compromised membrane asymmetry in senescent cells.
- StnIG induced ion influxes (Na+, Ca2+) and efflux (K+), leading to apoptosis and pyroptosis.
- StnIG synergized with chemotherapy to achieve tumor remission in mice.
Conclusions:
- StnI and StnIG function as senotoxins, selectively eliminating senescent cells.
- These senotoxins have potential as a novel therapeutic strategy to enhance cancer chemotherapy.
- StnIG demonstrates translational potential for improving solid tumor treatment outcomes.
More Related Videos
Related Concept Videos
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Regulation of Nuclear Protein Sorting
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
The Intrinsic Apoptotic Pathway


